Kyverna Therapeutics

Company snapshot

Kyverna is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kyverna Therapeutics. Not investment advice.

• Peer + 0 momentum

  Ultragenyx UK

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Kyverna Therapeutics.

1. Jun 8, 2026 Clinical update

   CCM-RNT-202402 — Phase 2

2. Jun 8, 2026 Clinical update

   KYV101-006 — Phase 3

3. Jun 8, 2026 Clinical update

   KYV101-007 — Phase 2

4. Jun 8, 2026 Clinical update

   KYV101-003 — Phase 2

5. Jun 5, 2026 Clinical update

   Standard of Care Treatment — Phase 3

View all clinical trial activity →

• What is Kyverna Therapeutics?

  Kyverna Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker KYTX. Primary therapeutic focus areas include Lupus Nephritis, Primary or Secondary Progressive Multiple Sclerosis, Generalized myasthenia gravis, ANCA-IgG-positive ANC

• Is Kyverna Therapeutics publicly traded?

  Yes. Kyverna Therapeutics is listed with ticker KYTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kyverna Therapeutics develop or market?

  We link 31 drug profile(s) where Kyverna Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kyverna-therapeutics#company-drugs.

• What are the latest developments for Kyverna Therapeutics?

  In the last 12 months our linked public records show 14 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kyverna Therapeutics focus on?

  Kyverna Therapeutics focuses on Lupus Nephritis, Primary or Secondary Progressive Multiple Sclerosis, Generalized myasthenia gravis based on our analysis of their pipeline programs and drug development activities.